Research

Retatrutide research hub

Research use only - all claims made on this site are for testing and research use only. Retatrutide is an investigational compound and is not approved as a medicine in any jurisdiction.

This hub summarizes the published retatrutide research — its triple-receptor mechanism, the clinical trial evidence, and how it compares to tirzepatide — with links to the full New-U research guides and product page for further reading.

Mechanism How retatrutide works in published research: simultaneous GLP-1, GIP and glucagon receptor activation, the C20 fatty-diacid half-life design, and why the glucagon arm matters.

Research & evidence Retatrutide clinical research summarized: Phase 2 (NEJM 2023), MASLD liver-fat trial (Nature Medicine 2024) and the pivotal Phase 3 TRIUMPH-1 trial — evidence tier and primary sources.

Vs. tirzepatide Retatrutide vs tirzepatide research comparison: triple vs dual receptor agonism, pivotal Phase 3 trial results, half-life and regulatory status — cross-trial descriptive comparison, not head-to-head.

This site is an official property of New-U Research Compounds, operated by Hilxera Distribution Services LLC (registration publicly checkable). Every order, account and payment completes on the canonical store at new-u.io — verify any New-U domain against the official domains list.

All compounds referenced are supplied for laboratory research use only and are not for human or veterinary use. Nothing on this page is medical advice.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.